Cancer Care

Fletcher Allen Breast Cancer Survival Rates

National Cancer Survival Database shows Fletcher Allen 2012 5-year survival rates were 79.2% compared to 66.1%. Learn more about Breast Cancer Treatment Survival Statistics.

It’s in the Numbers: Quality Cancer Care at Fletcher Allen

We are an American College of Surgeon’s Commission on Cancer (CoC) accredited program.  As part of this accreditation, Fletcher Allen submits data on compliance with six key metrics related to the standard of care therapies for breast, colon, and rectal cancers. 

These data are compiled annually into Cancer Program Practice Profile Reports (CP3R) which offer patients and providers meaningful information that helps us improve quality of patient care.  We are pleased to report that based on this data, Fletcher Allen outperforms other Commission on Cancer approved programs across the country in these metrics. 

 

Select Breast and Colorectal Measures  (2011 diagnosis year)

Fletcher Allen (%)

All CoC- approved programs (%)

BREAST: Radiation therapy is administered within one year (365 days) of diagnosis for women under age 70 receiving breast conserving surgery for breast cancer.  

98

89

BREAST: Combination chemotherapy is considered or administered within four months (120 days) of diagnosis for women under age 70 with AJCC T1cN0M0 or Stage II or III hormone receptor negative breast cancer.

92

90

BREAST: Tamoxifen or third generation aromatase inhibitor is considered or administered within one year (365 days) of diagnosis for women with AJCC T1cN0M0 or Stage II or III hormone receptor positive breast cancer.

98

84

COLON: At least 12 regional lymph nodes are removed and pathologically examined for resected colon cancer.

90

88

COLON: Adjuvant chemotherapy is considered or administered within four months (120 days) of diagnosis for patients under the age of 80 with AJCC Stage III (lymph node positive) colon cancer.

100

86

RECTAL: Radiation therapy is considered or administered within six months (180 days) of diagnosis for patients under the age of 80 with clinical or pathologic AJCC T4N0M0 or Stage III and who are receiving surgical resection for rectal cancer.

100

91